Announcement on Convening the 2025 Annual Performance Briefing
Filed with SSE · · 3 pages · Chinese
China Resources Double-Crane Pharmaceutical Co., Ltd. on 6ix
Earlier from China Resources Double-Crane Pharmaceutical
- Announcement on Implementing Repurchase and Cancellation under 2021 Restricted Stock Incentive Plan
- Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining the Drug Registration Certificate for Sodium Acetate Ringer's Injection
- Announcement on Wholly-owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. Obtaining Drug Registration Certificate for Balanced Salt Irrigation Solution
- Announcement on Drugs Being Selected for National Procurement Continuation After the Expiry of Agreement
- Announcement on Resolutions of the 17th Meeting of the 10th Board of Directors
Later from China Resources Double-Crane Pharmaceutical
- Announcement on Obtaining Drug Registration Certificate for Sodium Valproate Oral Solution by Holding Subsidiary Hunan Xiangzhong Pharmaceutical Co., Ltd.
- Announcement on Changing Registered Capital and Amending the Articles of Association
- Announcement on Obtaining Approval Notice for Drug Supplement Application by Wholly-Owned Subsidiary Xi'an Jingxi Double-Crane Pharmaceutical Co., Ltd. for Mannitol Injection
- Announcement on Lifting Sales Restrictions and Circulation of Restricted Stocks in 3rd Lifting Period of Initially Granted Part under Restricted Stock Incentive Plan of 2021
- Announcement on Convening the Q1 2026 Performance Briefing
Follow China Resources Double-Crane Pharmaceutical into a list and get an email when it puts out news.
Follow China Resources Double-Crane Pharmaceutical